nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP2D6—Lomustine—hematologic cancer	0.0333	0.0738	CbGbCtD
Lisuride—CYP2D6—Idarubicin—hematologic cancer	0.0296	0.0658	CbGbCtD
Lisuride—CYP2D6—Hydroxyurea—hematologic cancer	0.0252	0.0559	CbGbCtD
Lisuride—CYP3A4—Bexarotene—hematologic cancer	0.0227	0.0505	CbGbCtD
Lisuride—CYP2D6—Bortezomib—hematologic cancer	0.0219	0.0487	CbGbCtD
Lisuride—CYP3A4—Busulfan—hematologic cancer	0.0211	0.0469	CbGbCtD
Lisuride—CYP3A4—Lomustine—hematologic cancer	0.0211	0.0469	CbGbCtD
Lisuride—CYP3A4—Thiotepa—hematologic cancer	0.0188	0.0418	CbGbCtD
Lisuride—CYP2D6—Imatinib—hematologic cancer	0.0161	0.0357	CbGbCtD
Lisuride—CYP3A4—Methoxsalen—hematologic cancer	0.0147	0.0325	CbGbCtD
Lisuride—CYP2D6—Nilotinib—hematologic cancer	0.0146	0.0324	CbGbCtD
Lisuride—CYP2D6—Vinorelbine—hematologic cancer	0.0145	0.0321	CbGbCtD
Lisuride—CYP3A4—Bortezomib—hematologic cancer	0.0139	0.0309	CbGbCtD
Lisuride—CYP3A4—Daunorubicin—hematologic cancer	0.0133	0.0296	CbGbCtD
Lisuride—CYP3A4—Cytarabine—hematologic cancer	0.0118	0.0261	CbGbCtD
Lisuride—CYP3A4—Teniposide—hematologic cancer	0.0116	0.0257	CbGbCtD
Lisuride—CYP3A4—Ifosfamide—hematologic cancer	0.0107	0.0237	CbGbCtD
Lisuride—CYP3A4—Imatinib—hematologic cancer	0.0102	0.0227	CbGbCtD
Lisuride—CYP3A4—Ruxolitinib—hematologic cancer	0.00962	0.0213	CbGbCtD
Lisuride—CYP3A4—Nilotinib—hematologic cancer	0.00928	0.0206	CbGbCtD
Lisuride—CYP3A4—Vinorelbine—hematologic cancer	0.0092	0.0204	CbGbCtD
Lisuride—CYP2D6—Vinblastine—hematologic cancer	0.00892	0.0198	CbGbCtD
Lisuride—CYP3A4—Triamcinolone—hematologic cancer	0.00842	0.0187	CbGbCtD
Lisuride—CYP3A4—Dasatinib—hematologic cancer	0.0082	0.0182	CbGbCtD
Lisuride—CYP3A4—Mitoxantrone—hematologic cancer	0.0081	0.018	CbGbCtD
Lisuride—CYP3A4—Betamethasone—hematologic cancer	0.00722	0.016	CbGbCtD
Lisuride—CYP3A4—Prednisolone—hematologic cancer	0.00713	0.0158	CbGbCtD
Lisuride—CYP3A4—Prednisone—hematologic cancer	0.00673	0.0149	CbGbCtD
Lisuride—CYP2D6—Dexamethasone—hematologic cancer	0.00661	0.0147	CbGbCtD
Lisuride—CYP3A4—Irinotecan—hematologic cancer	0.00638	0.0142	CbGbCtD
Lisuride—CYP3A4—Vinblastine—hematologic cancer	0.00567	0.0126	CbGbCtD
Lisuride—CYP3A4—Vincristine—hematologic cancer	0.00558	0.0124	CbGbCtD
Lisuride—CYP2D6—Doxorubicin—hematologic cancer	0.00548	0.0122	CbGbCtD
Lisuride—CYP3A4—Etoposide—hematologic cancer	0.00511	0.0113	CbGbCtD
Lisuride—CYP3A4—Dexamethasone—hematologic cancer	0.0042	0.00932	CbGbCtD
Lisuride—CYP3A4—Doxorubicin—hematologic cancer	0.00349	0.00774	CbGbCtD
Lisuride—Fatigue—Irinotecan—hematologic cancer	0.000141	0.000381	CcSEcCtD
Lisuride—Fatigue—Mitoxantrone—hematologic cancer	0.000141	0.000381	CcSEcCtD
Lisuride—Vomiting—Lenalidomide—hematologic cancer	0.000141	0.00038	CcSEcCtD
Lisuride—Constipation—Mitoxantrone—hematologic cancer	0.00014	0.000378	CcSEcCtD
Lisuride—Constipation—Irinotecan—hematologic cancer	0.00014	0.000378	CcSEcCtD
Lisuride—Decreased appetite—Gemcitabine—hematologic cancer	0.000139	0.000375	CcSEcCtD
Lisuride—Vomiting—Hydroxyurea—hematologic cancer	0.000139	0.000374	CcSEcCtD
Lisuride—Headache—Lenalidomide—hematologic cancer	0.000139	0.000374	CcSEcCtD
Lisuride—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000138	0.000372	CcSEcCtD
Lisuride—Abdominal discomfort—Methotrexate—hematologic cancer	0.000138	0.000372	CcSEcCtD
Lisuride—Fatigue—Gemcitabine—hematologic cancer	0.000138	0.000372	CcSEcCtD
Lisuride—Confusional state—Etoposide—hematologic cancer	0.000138	0.000371	CcSEcCtD
Lisuride—Hallucination—Prednisone—hematologic cancer	0.000137	0.000369	CcSEcCtD
Lisuride—Headache—Hydroxyurea—hematologic cancer	0.000137	0.000369	CcSEcCtD
Lisuride—Constipation—Gemcitabine—hematologic cancer	0.000137	0.000369	CcSEcCtD
Lisuride—Asthenia—Thiotepa—hematologic cancer	0.000136	0.000368	CcSEcCtD
Lisuride—Vertigo—Triamcinolone—hematologic cancer	0.000136	0.000367	CcSEcCtD
Lisuride—Syncope—Triamcinolone—hematologic cancer	0.000136	0.000367	CcSEcCtD
Lisuride—Infection—Etoposide—hematologic cancer	0.000136	0.000366	CcSEcCtD
Lisuride—Feeling abnormal—Irinotecan—hematologic cancer	0.000135	0.000365	CcSEcCtD
Lisuride—Feeling abnormal—Mitoxantrone—hematologic cancer	0.000135	0.000365	CcSEcCtD
Lisuride—Dizziness—Bortezomib—hematologic cancer	0.000135	0.000363	CcSEcCtD
Lisuride—Dehydration—Doxorubicin—hematologic cancer	0.000134	0.000361	CcSEcCtD
Lisuride—Tachycardia—Etoposide—hematologic cancer	0.000133	0.000359	CcSEcCtD
Lisuride—Dyspnoea—Cisplatin—hematologic cancer	0.000133	0.000358	CcSEcCtD
Lisuride—Cough—Triamcinolone—hematologic cancer	0.000132	0.000357	CcSEcCtD
Lisuride—Hyperhidrosis—Etoposide—hematologic cancer	0.000132	0.000356	CcSEcCtD
Lisuride—Asthenia—Thalidomide—hematologic cancer	0.000132	0.000356	CcSEcCtD
Lisuride—Feeling abnormal—Gemcitabine—hematologic cancer	0.000132	0.000355	CcSEcCtD
Lisuride—Dizziness—Vinorelbine—hematologic cancer	0.000132	0.000355	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—hematologic cancer	0.000132	0.000355	CcSEcCtD
Lisuride—Tachycardia—Prednisolone—hematologic cancer	0.000131	0.000354	CcSEcCtD
Lisuride—Hyperhidrosis—Prednisolone—hematologic cancer	0.00013	0.000351	CcSEcCtD
Lisuride—Anorexia—Etoposide—hematologic cancer	0.00013	0.000351	CcSEcCtD
Lisuride—Vomiting—Bortezomib—hematologic cancer	0.00013	0.000349	CcSEcCtD
Lisuride—Decreased appetite—Cisplatin—hematologic cancer	0.000129	0.000349	CcSEcCtD
Lisuride—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.000129	0.000347	CcSEcCtD
Lisuride—Vomiting—Bleomycin—hematologic cancer	0.000129	0.000347	CcSEcCtD
Lisuride—Headache—Bortezomib—hematologic cancer	0.000128	0.000344	CcSEcCtD
Lisuride—Asthenia—Carmustine—hematologic cancer	0.000127	0.000341	CcSEcCtD
Lisuride—Vomiting—Vinorelbine—hematologic cancer	0.000126	0.000341	CcSEcCtD
Lisuride—Dry mouth—Triamcinolone—hematologic cancer	0.000126	0.000341	CcSEcCtD
Lisuride—Dizziness—Thiotepa—hematologic cancer	0.000126	0.000339	CcSEcCtD
Lisuride—Asthenia—Alitretinoin—hematologic cancer	0.000125	0.000338	CcSEcCtD
Lisuride—Angiopathy—Prednisone—hematologic cancer	0.000125	0.000337	CcSEcCtD
Lisuride—Headache—Vinorelbine—hematologic cancer	0.000125	0.000336	CcSEcCtD
Lisuride—Immune system disorder—Prednisone—hematologic cancer	0.000124	0.000335	CcSEcCtD
Lisuride—Asthenia—Ifosfamide—hematologic cancer	0.000124	0.000334	CcSEcCtD
Lisuride—Vertigo—Dexamethasone—hematologic cancer	0.000124	0.000333	CcSEcCtD
Lisuride—Vertigo—Betamethasone—hematologic cancer	0.000124	0.000333	CcSEcCtD
Lisuride—Syncope—Dexamethasone—hematologic cancer	0.000123	0.000333	CcSEcCtD
Lisuride—Syncope—Betamethasone—hematologic cancer	0.000123	0.000333	CcSEcCtD
Lisuride—Infection—Triamcinolone—hematologic cancer	0.000123	0.000332	CcSEcCtD
Lisuride—Sweating—Methotrexate—hematologic cancer	0.000123	0.000331	CcSEcCtD
Lisuride—Feeling abnormal—Cisplatin—hematologic cancer	0.000123	0.000331	CcSEcCtD
Lisuride—Weight increased—Epirubicin—hematologic cancer	0.000122	0.00033	CcSEcCtD
Lisuride—Insomnia—Prednisolone—hematologic cancer	0.000122	0.000328	CcSEcCtD
Lisuride—Weight decreased—Epirubicin—hematologic cancer	0.000122	0.000328	CcSEcCtD
Lisuride—Dyspnoea—Etoposide—hematologic cancer	0.000122	0.000328	CcSEcCtD
Lisuride—Dizziness—Thalidomide—hematologic cancer	0.000122	0.000328	CcSEcCtD
Lisuride—Somnolence—Etoposide—hematologic cancer	0.000121	0.000327	CcSEcCtD
Lisuride—Asthenia—Vincristine—hematologic cancer	0.000121	0.000326	CcSEcCtD
Lisuride—Tachycardia—Triamcinolone—hematologic cancer	0.000121	0.000326	CcSEcCtD
Lisuride—Vomiting—Thiotepa—hematologic cancer	0.000121	0.000326	CcSEcCtD
Lisuride—Mental disorder—Prednisone—hematologic cancer	0.000121	0.000325	CcSEcCtD
Lisuride—Malnutrition—Prednisone—hematologic cancer	0.00012	0.000323	CcSEcCtD
Lisuride—Hyperhidrosis—Triamcinolone—hematologic cancer	0.00012	0.000323	CcSEcCtD
Lisuride—Headache—Thiotepa—hematologic cancer	0.000119	0.000321	CcSEcCtD
Lisuride—Decreased appetite—Etoposide—hematologic cancer	0.000119	0.00032	CcSEcCtD
Lisuride—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000118	0.000318	CcSEcCtD
Lisuride—Asthenia—Mitoxantrone—hematologic cancer	0.000118	0.000317	CcSEcCtD
Lisuride—Asthenia—Irinotecan—hematologic cancer	0.000118	0.000317	CcSEcCtD
Lisuride—Fatigue—Etoposide—hematologic cancer	0.000118	0.000317	CcSEcCtD
Lisuride—Vomiting—Thalidomide—hematologic cancer	0.000117	0.000315	CcSEcCtD
Lisuride—Anxiety—Dexamethasone—hematologic cancer	0.000117	0.000315	CcSEcCtD
Lisuride—Anxiety—Betamethasone—hematologic cancer	0.000117	0.000315	CcSEcCtD
Lisuride—Dizziness—Carmustine—hematologic cancer	0.000117	0.000315	CcSEcCtD
Lisuride—Constipation—Etoposide—hematologic cancer	0.000117	0.000315	CcSEcCtD
Lisuride—Dizziness—Alitretinoin—hematologic cancer	0.000116	0.000312	CcSEcCtD
Lisuride—Headache—Thalidomide—hematologic cancer	0.000115	0.00031	CcSEcCtD
Lisuride—Sweating—Epirubicin—hematologic cancer	0.000115	0.00031	CcSEcCtD
Lisuride—Asthenia—Gemcitabine—hematologic cancer	0.000115	0.000309	CcSEcCtD
Lisuride—Dizziness—Ifosfamide—hematologic cancer	0.000114	0.000308	CcSEcCtD
Lisuride—Weight increased—Doxorubicin—hematologic cancer	0.000113	0.000305	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—hematologic cancer	0.000113	0.000304	CcSEcCtD
Lisuride—Feeling abnormal—Etoposide—hematologic cancer	0.000112	0.000303	CcSEcCtD
Lisuride—Vomiting—Carmustine—hematologic cancer	0.000112	0.000303	CcSEcCtD
Lisuride—Insomnia—Triamcinolone—hematologic cancer	0.000112	0.000302	CcSEcCtD
Lisuride—Infection—Dexamethasone—hematologic cancer	0.000112	0.000301	CcSEcCtD
Lisuride—Infection—Betamethasone—hematologic cancer	0.000112	0.000301	CcSEcCtD
Lisuride—Dizziness—Vincristine—hematologic cancer	0.000111	0.0003	CcSEcCtD
Lisuride—Vomiting—Alitretinoin—hematologic cancer	0.000111	0.0003	CcSEcCtD
Lisuride—Feeling abnormal—Prednisolone—hematologic cancer	0.000111	0.000299	CcSEcCtD
Lisuride—Headache—Carmustine—hematologic cancer	0.000111	0.000298	CcSEcCtD
Lisuride—Dyspnoea—Triamcinolone—hematologic cancer	0.00011	0.000298	CcSEcCtD
Lisuride—Nervous system disorder—Betamethasone—hematologic cancer	0.00011	0.000297	CcSEcCtD
Lisuride—Nervous system disorder—Dexamethasone—hematologic cancer	0.00011	0.000297	CcSEcCtD
Lisuride—Vomiting—Ifosfamide—hematologic cancer	0.00011	0.000296	CcSEcCtD
Lisuride—Tachycardia—Betamethasone—hematologic cancer	0.00011	0.000296	CcSEcCtD
Lisuride—Tachycardia—Dexamethasone—hematologic cancer	0.00011	0.000296	CcSEcCtD
Lisuride—Headache—Alitretinoin—hematologic cancer	0.00011	0.000295	CcSEcCtD
Lisuride—Hyperhidrosis—Betamethasone—hematologic cancer	0.000109	0.000293	CcSEcCtD
Lisuride—Hyperhidrosis—Dexamethasone—hematologic cancer	0.000109	0.000293	CcSEcCtD
Lisuride—Dizziness—Irinotecan—hematologic cancer	0.000108	0.000293	CcSEcCtD
Lisuride—Vertigo—Prednisone—hematologic cancer	0.000108	0.00029	CcSEcCtD
Lisuride—Syncope—Prednisone—hematologic cancer	0.000107	0.00029	CcSEcCtD
Lisuride—Vomiting—Vincristine—hematologic cancer	0.000107	0.000289	CcSEcCtD
Lisuride—Anorexia—Betamethasone—hematologic cancer	0.000107	0.000289	CcSEcCtD
Lisuride—Anorexia—Dexamethasone—hematologic cancer	0.000107	0.000289	CcSEcCtD
Lisuride—Asthenia—Cisplatin—hematologic cancer	0.000107	0.000288	CcSEcCtD
Lisuride—Cardiac disorder—Methotrexate—hematologic cancer	0.000107	0.000288	CcSEcCtD
Lisuride—Fatigue—Triamcinolone—hematologic cancer	0.000107	0.000288	CcSEcCtD
Lisuride—Sweating—Doxorubicin—hematologic cancer	0.000106	0.000287	CcSEcCtD
Lisuride—Oedema peripheral—Epirubicin—hematologic cancer	0.000106	0.000286	CcSEcCtD
Lisuride—Headache—Vincristine—hematologic cancer	0.000106	0.000285	CcSEcCtD
Lisuride—Angiopathy—Methotrexate—hematologic cancer	0.000104	0.000282	CcSEcCtD
Lisuride—Vomiting—Irinotecan—hematologic cancer	0.000104	0.000281	CcSEcCtD
Lisuride—Vomiting—Mitoxantrone—hematologic cancer	0.000104	0.000281	CcSEcCtD
Lisuride—Immune system disorder—Methotrexate—hematologic cancer	0.000104	0.00028	CcSEcCtD
Lisuride—Mediastinal disorder—Methotrexate—hematologic cancer	0.000104	0.00028	CcSEcCtD
Lisuride—Headache—Mitoxantrone—hematologic cancer	0.000103	0.000277	CcSEcCtD
Lisuride—Headache—Irinotecan—hematologic cancer	0.000103	0.000277	CcSEcCtD
Lisuride—Feeling abnormal—Triamcinolone—hematologic cancer	0.000102	0.000275	CcSEcCtD
Lisuride—Anxiety—Prednisone—hematologic cancer	0.000102	0.000274	CcSEcCtD
Lisuride—Vomiting—Gemcitabine—hematologic cancer	0.000102	0.000274	CcSEcCtD
Lisuride—Insomnia—Dexamethasone—hematologic cancer	0.000102	0.000274	CcSEcCtD
Lisuride—Insomnia—Betamethasone—hematologic cancer	0.000102	0.000274	CcSEcCtD
Lisuride—Mental disorder—Methotrexate—hematologic cancer	0.000101	0.000272	CcSEcCtD
Lisuride—Malnutrition—Methotrexate—hematologic cancer	0.0001	0.00027	CcSEcCtD
Lisuride—Headache—Gemcitabine—hematologic cancer	0.0001	0.00027	CcSEcCtD
Lisuride—Cardiac disorder—Epirubicin—hematologic cancer	9.99e-05	0.000269	CcSEcCtD
Lisuride—Oedema peripheral—Doxorubicin—hematologic cancer	9.81e-05	0.000265	CcSEcCtD
Lisuride—Asthenia—Etoposide—hematologic cancer	9.79e-05	0.000264	CcSEcCtD
Lisuride—Angiopathy—Epirubicin—hematologic cancer	9.77e-05	0.000263	CcSEcCtD
Lisuride—Decreased appetite—Dexamethasone—hematologic cancer	9.76e-05	0.000263	CcSEcCtD
Lisuride—Decreased appetite—Betamethasone—hematologic cancer	9.76e-05	0.000263	CcSEcCtD
Lisuride—Immune system disorder—Epirubicin—hematologic cancer	9.73e-05	0.000262	CcSEcCtD
Lisuride—Infection—Prednisone—hematologic cancer	9.72e-05	0.000262	CcSEcCtD
Lisuride—Mediastinal disorder—Epirubicin—hematologic cancer	9.7e-05	0.000262	CcSEcCtD
Lisuride—Gastrointestinal disorder—Dexamethasone—hematologic cancer	9.7e-05	0.000261	CcSEcCtD
Lisuride—Gastrointestinal disorder—Betamethasone—hematologic cancer	9.7e-05	0.000261	CcSEcCtD
Lisuride—Fatigue—Betamethasone—hematologic cancer	9.68e-05	0.000261	CcSEcCtD
Lisuride—Fatigue—Dexamethasone—hematologic cancer	9.68e-05	0.000261	CcSEcCtD
Lisuride—Nervous system disorder—Prednisone—hematologic cancer	9.59e-05	0.000259	CcSEcCtD
Lisuride—Tachycardia—Prednisone—hematologic cancer	9.55e-05	0.000257	CcSEcCtD
Lisuride—Vomiting—Cisplatin—hematologic cancer	9.47e-05	0.000255	CcSEcCtD
Lisuride—Hyperhidrosis—Prednisone—hematologic cancer	9.46e-05	0.000255	CcSEcCtD
Lisuride—Mental disorder—Epirubicin—hematologic cancer	9.43e-05	0.000254	CcSEcCtD
Lisuride—Malnutrition—Epirubicin—hematologic cancer	9.37e-05	0.000253	CcSEcCtD
Lisuride—Anorexia—Prednisone—hematologic cancer	9.32e-05	0.000251	CcSEcCtD
Lisuride—Feeling abnormal—Betamethasone—hematologic cancer	9.26e-05	0.00025	CcSEcCtD
Lisuride—Feeling abnormal—Dexamethasone—hematologic cancer	9.26e-05	0.00025	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—hematologic cancer	9.25e-05	0.000249	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—hematologic cancer	9.04e-05	0.000244	CcSEcCtD
Lisuride—Dizziness—Etoposide—hematologic cancer	9.02e-05	0.000243	CcSEcCtD
Lisuride—Immune system disorder—Doxorubicin—hematologic cancer	9e-05	0.000243	CcSEcCtD
Lisuride—Vertigo—Methotrexate—hematologic cancer	9e-05	0.000243	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—hematologic cancer	8.98e-05	0.000242	CcSEcCtD
Lisuride—Dizziness—Prednisolone—hematologic cancer	8.9e-05	0.00024	CcSEcCtD
Lisuride—Asthenia—Triamcinolone—hematologic cancer	8.88e-05	0.000239	CcSEcCtD
Lisuride—Insomnia—Prednisone—hematologic cancer	8.85e-05	0.000239	CcSEcCtD
Lisuride—Cough—Methotrexate—hematologic cancer	8.74e-05	0.000236	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—hematologic cancer	8.73e-05	0.000235	CcSEcCtD
Lisuride—Vomiting—Etoposide—hematologic cancer	8.68e-05	0.000234	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—hematologic cancer	8.67e-05	0.000234	CcSEcCtD
Lisuride—Headache—Etoposide—hematologic cancer	8.55e-05	0.000231	CcSEcCtD
Lisuride—Decreased appetite—Prednisone—hematologic cancer	8.5e-05	0.000229	CcSEcCtD
Lisuride—Fatigue—Prednisone—hematologic cancer	8.43e-05	0.000227	CcSEcCtD
Lisuride—Headache—Prednisolone—hematologic cancer	8.43e-05	0.000227	CcSEcCtD
Lisuride—Vertigo—Epirubicin—hematologic cancer	8.42e-05	0.000227	CcSEcCtD
Lisuride—Syncope—Epirubicin—hematologic cancer	8.41e-05	0.000227	CcSEcCtD
Lisuride—Constipation—Prednisone—hematologic cancer	8.36e-05	0.000226	CcSEcCtD
Lisuride—Palpitations—Epirubicin—hematologic cancer	8.28e-05	0.000223	CcSEcCtD
Lisuride—Confusional state—Methotrexate—hematologic cancer	8.24e-05	0.000222	CcSEcCtD
Lisuride—Dizziness—Triamcinolone—hematologic cancer	8.19e-05	0.000221	CcSEcCtD
Lisuride—Cough—Epirubicin—hematologic cancer	8.18e-05	0.000221	CcSEcCtD
Lisuride—Infection—Methotrexate—hematologic cancer	8.12e-05	0.000219	CcSEcCtD
Lisuride—Feeling abnormal—Prednisone—hematologic cancer	8.06e-05	0.000217	CcSEcCtD
Lisuride—Asthenia—Betamethasone—hematologic cancer	8.06e-05	0.000217	CcSEcCtD
Lisuride—Asthenia—Dexamethasone—hematologic cancer	8.06e-05	0.000217	CcSEcCtD
Lisuride—Nervous system disorder—Methotrexate—hematologic cancer	8.02e-05	0.000216	CcSEcCtD
Lisuride—Anxiety—Epirubicin—hematologic cancer	7.95e-05	0.000214	CcSEcCtD
Lisuride—Hyperhidrosis—Methotrexate—hematologic cancer	7.9e-05	0.000213	CcSEcCtD
Lisuride—Vomiting—Triamcinolone—hematologic cancer	7.87e-05	0.000212	CcSEcCtD
Lisuride—Dry mouth—Epirubicin—hematologic cancer	7.8e-05	0.00021	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—hematologic cancer	7.79e-05	0.00021	CcSEcCtD
Lisuride—Anorexia—Methotrexate—hematologic cancer	7.79e-05	0.00021	CcSEcCtD
Lisuride—Syncope—Doxorubicin—hematologic cancer	7.78e-05	0.00021	CcSEcCtD
Lisuride—Headache—Triamcinolone—hematologic cancer	7.75e-05	0.000209	CcSEcCtD
Lisuride—Confusional state—Epirubicin—hematologic cancer	7.71e-05	0.000208	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—hematologic cancer	7.66e-05	0.000207	CcSEcCtD
Lisuride—Infection—Epirubicin—hematologic cancer	7.6e-05	0.000205	CcSEcCtD
Lisuride—Cough—Doxorubicin—hematologic cancer	7.57e-05	0.000204	CcSEcCtD
Lisuride—Nervous system disorder—Epirubicin—hematologic cancer	7.5e-05	0.000202	CcSEcCtD
Lisuride—Tachycardia—Epirubicin—hematologic cancer	7.47e-05	0.000201	CcSEcCtD
Lisuride—Dizziness—Betamethasone—hematologic cancer	7.43e-05	0.0002	CcSEcCtD
Lisuride—Dizziness—Dexamethasone—hematologic cancer	7.43e-05	0.0002	CcSEcCtD
Lisuride—Hyperhidrosis—Epirubicin—hematologic cancer	7.4e-05	0.000199	CcSEcCtD
Lisuride—Insomnia—Methotrexate—hematologic cancer	7.39e-05	0.000199	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—hematologic cancer	7.36e-05	0.000198	CcSEcCtD
Lisuride—Anorexia—Epirubicin—hematologic cancer	7.29e-05	0.000197	CcSEcCtD
Lisuride—Dyspnoea—Methotrexate—hematologic cancer	7.29e-05	0.000197	CcSEcCtD
Lisuride—Somnolence—Methotrexate—hematologic cancer	7.27e-05	0.000196	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—hematologic cancer	7.22e-05	0.000195	CcSEcCtD
Lisuride—Vomiting—Dexamethasone—hematologic cancer	7.14e-05	0.000193	CcSEcCtD
Lisuride—Vomiting—Betamethasone—hematologic cancer	7.14e-05	0.000193	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—hematologic cancer	7.14e-05	0.000192	CcSEcCtD
Lisuride—Decreased appetite—Methotrexate—hematologic cancer	7.11e-05	0.000192	CcSEcCtD
Lisuride—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.06e-05	0.00019	CcSEcCtD
Lisuride—Fatigue—Methotrexate—hematologic cancer	7.05e-05	0.00019	CcSEcCtD
Lisuride—Headache—Betamethasone—hematologic cancer	7.04e-05	0.00019	CcSEcCtD
Lisuride—Headache—Dexamethasone—hematologic cancer	7.04e-05	0.00019	CcSEcCtD
Lisuride—Infection—Doxorubicin—hematologic cancer	7.03e-05	0.00019	CcSEcCtD
Lisuride—Asthenia—Prednisone—hematologic cancer	7.02e-05	0.000189	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—hematologic cancer	6.94e-05	0.000187	CcSEcCtD
Lisuride—Insomnia—Epirubicin—hematologic cancer	6.92e-05	0.000187	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—hematologic cancer	6.91e-05	0.000186	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—hematologic cancer	6.84e-05	0.000185	CcSEcCtD
Lisuride—Dyspnoea—Epirubicin—hematologic cancer	6.82e-05	0.000184	CcSEcCtD
Lisuride—Somnolence—Epirubicin—hematologic cancer	6.8e-05	0.000183	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—hematologic cancer	6.75e-05	0.000182	CcSEcCtD
Lisuride—Feeling abnormal—Methotrexate—hematologic cancer	6.74e-05	0.000182	CcSEcCtD
Lisuride—Decreased appetite—Epirubicin—hematologic cancer	6.65e-05	0.000179	CcSEcCtD
Lisuride—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.6e-05	0.000178	CcSEcCtD
Lisuride—Fatigue—Epirubicin—hematologic cancer	6.6e-05	0.000178	CcSEcCtD
Lisuride—Constipation—Epirubicin—hematologic cancer	6.54e-05	0.000176	CcSEcCtD
Lisuride—Dizziness—Prednisone—hematologic cancer	6.47e-05	0.000174	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—hematologic cancer	6.4e-05	0.000173	CcSEcCtD
Lisuride—Dyspnoea—Doxorubicin—hematologic cancer	6.31e-05	0.00017	CcSEcCtD
Lisuride—Feeling abnormal—Epirubicin—hematologic cancer	6.3e-05	0.00017	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—hematologic cancer	6.29e-05	0.00017	CcSEcCtD
Lisuride—Vomiting—Prednisone—hematologic cancer	6.22e-05	0.000168	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—hematologic cancer	6.15e-05	0.000166	CcSEcCtD
Lisuride—Headache—Prednisone—hematologic cancer	6.13e-05	0.000165	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.11e-05	0.000165	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—hematologic cancer	6.1e-05	0.000165	CcSEcCtD
Lisuride—Constipation—Doxorubicin—hematologic cancer	6.05e-05	0.000163	CcSEcCtD
Lisuride—Asthenia—Methotrexate—hematologic cancer	5.86e-05	0.000158	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—hematologic cancer	5.83e-05	0.000157	CcSEcCtD
Lisuride—Asthenia—Epirubicin—hematologic cancer	5.49e-05	0.000148	CcSEcCtD
Lisuride—Dizziness—Methotrexate—hematologic cancer	5.41e-05	0.000146	CcSEcCtD
Lisuride—Vomiting—Methotrexate—hematologic cancer	5.2e-05	0.00014	CcSEcCtD
Lisuride—Headache—Methotrexate—hematologic cancer	5.12e-05	0.000138	CcSEcCtD
Lisuride—Asthenia—Doxorubicin—hematologic cancer	5.08e-05	0.000137	CcSEcCtD
Lisuride—Dizziness—Epirubicin—hematologic cancer	5.06e-05	0.000136	CcSEcCtD
Lisuride—Vomiting—Epirubicin—hematologic cancer	4.86e-05	0.000131	CcSEcCtD
Lisuride—Headache—Epirubicin—hematologic cancer	4.79e-05	0.000129	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—hematologic cancer	4.68e-05	0.000126	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—hematologic cancer	4.5e-05	0.000121	CcSEcCtD
Lisuride—Headache—Doxorubicin—hematologic cancer	4.43e-05	0.00012	CcSEcCtD
Lisuride—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	3.69e-06	2.07e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HRAS—hematologic cancer	3.69e-06	2.06e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	3.69e-06	2.06e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—SRC—hematologic cancer	3.69e-06	2.06e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	3.68e-06	2.06e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—hematologic cancer	3.67e-06	2.06e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TGFB1—hematologic cancer	3.66e-06	2.05e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—SRC—hematologic cancer	3.65e-06	2.04e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	3.64e-06	2.04e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	3.63e-06	2.03e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	3.63e-06	2.03e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EP300—hematologic cancer	3.63e-06	2.03e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—hematologic cancer	3.62e-06	2.03e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	3.62e-06	2.03e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—hematologic cancer	3.62e-06	2.03e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	3.62e-06	2.03e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	3.62e-06	2.02e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TGFB1—hematologic cancer	3.62e-06	2.02e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EP300—hematologic cancer	3.61e-06	2.02e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—hematologic cancer	3.6e-06	2.02e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	3.6e-06	2.01e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	3.6e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	3.59e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	3.59e-06	2.01e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	3.59e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—hematologic cancer	3.57e-06	2e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	3.57e-06	2e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	3.57e-06	2e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	3.56e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—hematologic cancer	3.55e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	3.55e-06	1.99e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—hematologic cancer	3.55e-06	1.99e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—hematologic cancer	3.55e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NRAS—hematologic cancer	3.55e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	3.54e-06	1.98e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	3.53e-06	1.98e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—hematologic cancer	3.53e-06	1.98e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	3.53e-06	1.98e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—SRC—hematologic cancer	3.53e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	3.52e-06	1.97e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	3.52e-06	1.97e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.52e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	3.51e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EP300—hematologic cancer	3.51e-06	1.96e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—SRC—hematologic cancer	3.51e-06	1.96e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—hematologic cancer	3.5e-06	1.96e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—hematologic cancer	3.49e-06	1.95e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—hematologic cancer	3.48e-06	1.95e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—hematologic cancer	3.47e-06	1.94e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	3.46e-06	1.94e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—hematologic cancer	3.46e-06	1.94e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	3.46e-06	1.94e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	3.46e-06	1.94e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EP300—hematologic cancer	3.45e-06	1.93e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—JUN—hematologic cancer	3.45e-06	1.93e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	3.43e-06	1.92e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	3.42e-06	1.91e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—SRC—hematologic cancer	3.41e-06	1.91e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—EP300—hematologic cancer	3.41e-06	1.91e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—hematologic cancer	3.41e-06	1.91e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—hematologic cancer	3.4e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—hematologic cancer	3.4e-06	1.9e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	3.4e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—JUN—hematologic cancer	3.4e-06	1.9e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—hematologic cancer	3.39e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NRAS—hematologic cancer	3.39e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—hematologic cancer	3.38e-06	1.89e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NRAS—hematologic cancer	3.37e-06	1.89e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.37e-06	1.89e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	3.36e-06	1.88e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—SRC—hematologic cancer	3.36e-06	1.88e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—hematologic cancer	3.35e-06	1.88e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	3.35e-06	1.88e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—hematologic cancer	3.35e-06	1.88e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	3.35e-06	1.87e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—hematologic cancer	3.34e-06	1.87e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—hematologic cancer	3.33e-06	1.86e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	3.32e-06	1.86e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	3.31e-06	1.85e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—hematologic cancer	3.3e-06	1.85e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	3.3e-06	1.85e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	3.29e-06	1.84e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	3.29e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	3.29e-06	1.84e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—hematologic cancer	3.28e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	3.28e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—hematologic cancer	3.27e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	3.27e-06	1.83e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK8—hematologic cancer	3.26e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	3.26e-06	1.83e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.26e-06	1.83e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—hematologic cancer	3.26e-06	1.82e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—hematologic cancer	3.26e-06	1.82e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	3.25e-06	1.82e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	3.24e-06	1.82e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	3.24e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	3.23e-06	1.81e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	3.23e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	3.21e-06	1.8e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	3.21e-06	1.8e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—hematologic cancer	3.2e-06	1.79e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	3.2e-06	1.79e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—hematologic cancer	3.2e-06	1.79e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.19e-06	1.79e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—hematologic cancer	3.18e-06	1.78e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EP300—hematologic cancer	3.18e-06	1.78e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	3.18e-06	1.78e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—hematologic cancer	3.18e-06	1.78e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	3.16e-06	1.77e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—hematologic cancer	3.16e-06	1.77e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	3.15e-06	1.76e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	3.14e-06	1.76e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—hematologic cancer	3.14e-06	1.76e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	3.14e-06	1.76e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EP300—hematologic cancer	3.13e-06	1.75e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	3.12e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—hematologic cancer	3.12e-06	1.75e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—hematologic cancer	3.1e-06	1.74e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.1e-06	1.73e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.1e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	3.1e-06	1.73e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SRC—hematologic cancer	3.1e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	3.09e-06	1.73e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.09e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—JUN—hematologic cancer	3.09e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	3.08e-06	1.72e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	3.08e-06	1.72e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—hematologic cancer	3.07e-06	1.72e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—hematologic cancer	3.06e-06	1.71e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—hematologic cancer	3.06e-06	1.71e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—hematologic cancer	3.05e-06	1.71e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ALB—hematologic cancer	3.05e-06	1.71e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	3.05e-06	1.71e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SRC—hematologic cancer	3.05e-06	1.71e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	3.02e-06	1.69e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—hematologic cancer	3.02e-06	1.69e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—hematologic cancer	3.01e-06	1.69e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—hematologic cancer	3.01e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	3e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	2.99e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	2.99e-06	1.67e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—hematologic cancer	2.98e-06	1.67e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NRAS—hematologic cancer	2.98e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—hematologic cancer	2.98e-06	1.67e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—hematologic cancer	2.98e-06	1.67e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	2.97e-06	1.66e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—hematologic cancer	2.94e-06	1.64e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—hematologic cancer	2.94e-06	1.64e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NRAS—hematologic cancer	2.93e-06	1.64e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—hematologic cancer	2.93e-06	1.64e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	2.92e-06	1.64e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.92e-06	1.63e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—hematologic cancer	2.92e-06	1.63e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	2.91e-06	1.63e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.9e-06	1.63e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—hematologic cancer	2.89e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—hematologic cancer	2.88e-06	1.61e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—hematologic cancer	2.85e-06	1.6e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EP300—hematologic cancer	2.85e-06	1.6e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—hematologic cancer	2.85e-06	1.59e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	2.85e-06	1.59e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—hematologic cancer	2.83e-06	1.58e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	2.82e-06	1.58e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	2.81e-06	1.57e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	2.8e-06	1.57e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.78e-06	1.56e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	2.78e-06	1.56e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SRC—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TGFB1—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—hematologic cancer	2.76e-06	1.55e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.74e-06	1.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.73e-06	1.53e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—hematologic cancer	2.72e-06	1.53e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—hematologic cancer	2.72e-06	1.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.72e-06	1.52e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—hematologic cancer	2.71e-06	1.52e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—hematologic cancer	2.7e-06	1.51e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	2.7e-06	1.51e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.69e-06	1.51e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—hematologic cancer	2.69e-06	1.5e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	2.68e-06	1.5e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	2.67e-06	1.5e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.67e-06	1.49e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	2.67e-06	1.49e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	2.59e-06	1.45e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—hematologic cancer	2.59e-06	1.45e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—hematologic cancer	2.59e-06	1.45e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.58e-06	1.44e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	2.57e-06	1.44e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—hematologic cancer	2.56e-06	1.43e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.55e-06	1.43e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	2.55e-06	1.43e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—hematologic cancer	2.55e-06	1.43e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—hematologic cancer	2.54e-06	1.42e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2.52e-06	1.41e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—hematologic cancer	2.52e-06	1.41e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	2.51e-06	1.41e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—hematologic cancer	2.51e-06	1.41e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—hematologic cancer	2.51e-06	1.41e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—hematologic cancer	2.48e-06	1.39e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—hematologic cancer	2.48e-06	1.39e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—hematologic cancer	2.48e-06	1.39e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	2.48e-06	1.39e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.47e-06	1.38e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.47e-06	1.38e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—hematologic cancer	2.46e-06	1.38e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	2.4e-06	1.34e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—hematologic cancer	2.37e-06	1.33e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	2.36e-06	1.32e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—hematologic cancer	2.36e-06	1.32e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	2.35e-06	1.32e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—hematologic cancer	2.33e-06	1.3e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	2.32e-06	1.3e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.3e-06	1.29e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—hematologic cancer	2.3e-06	1.29e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	2.29e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—hematologic cancer	2.29e-06	1.28e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—hematologic cancer	2.28e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	2.27e-06	1.27e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—hematologic cancer	2.26e-06	1.27e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—hematologic cancer	2.24e-06	1.25e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—EP300—hematologic cancer	2.22e-06	1.24e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—hematologic cancer	2.19e-06	1.23e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—hematologic cancer	2.18e-06	1.22e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—hematologic cancer	2.18e-06	1.22e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—hematologic cancer	2.14e-06	1.2e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.13e-06	1.19e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	2.12e-06	1.19e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	2.11e-06	1.18e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	2.09e-06	1.17e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—hematologic cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—hematologic cancer	2.06e-06	1.15e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—hematologic cancer	2.05e-06	1.15e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—hematologic cancer	2.04e-06	1.14e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.02e-06	1.13e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ALB—hematologic cancer	2e-06	1.12e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.95e-06	1.09e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.92e-06	1.08e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.91e-06	1.07e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.89e-06	1.06e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.87e-06	1.04e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.76e-06	9.86e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.72e-06	9.64e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.64e-06	9.2e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—hematologic cancer	1.52e-06	8.52e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—EP300—hematologic cancer	1.45e-06	8.13e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—hematologic cancer	1.34e-06	7.51e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.07e-06	6.01e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—hematologic cancer	8.77e-07	4.91e-06	CbGpPWpGaD
